Novo Nordisk to build insulin plant in Russia
This article was originally published in Scrip
Executive Summary
Novo Nordisk's president and CEO Lars Sorensen and the head of its Russian subsidiary Sergey Smirnov have signed a letter of intent with the local government to build an insulin production facility in the Tech Park Grabtsevo near Kaluga, a city 200km southwest of Moscow.